BCAB - BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7 2023 | Benzinga
- Submitted abstract on CAB-AXL-ADC, BA3011, in non-small cell lung cancer (NSCLC) to the IASLC 2023 North America Conference on Lung Cancer; KOL event planned for December 4, 2023, following conclusion of the IASLC conference
- R&D day planned for December 13, 2023, to discuss BA3071 (CAB-CTLA-4) Phase 1/2 basket trial
- Management to host third quarter 2023 financial results conference call and webcast on Tuesday, November 7, 2023 at 4:30 PM Eastern Time
SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today provided guidance on near-term milestones and announced that it plans to host a conference call and webcast on Tuesday, November 7, 2023 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2023 and provide business highlights.
Third Quarter 2023 ...